A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Amrubicin (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 11 Jan 2017 protocol was amended to update the primary endpoint and its time frame.
- 11 Jan 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
- 22 Nov 2014 According to ClinicalTrial.gov record, planned End Date changed from 1 May 2015 to 1 Jul 2016.